REWIND | ACROSS T2D

REWIND

The REWIND CVOT assessed the cardiovascular safety of dulaglutide in patients with type 2 diabetes with high CV risk, or prior CV events. This module details the results.

REWIND

REWIND
REWIND
Login or create an account to see restricted content
REWIND
Login or create an account to see restricted content
REWIND: trial design
Login or create an account to see restricted content
REWIND: key inclusion and exclusion criteria
Login or create an account to see restricted content
REWIND: key inclusion criteria by age and CV disease or risk factors
Login or create an account to see restricted content
REWIND: graphical representation of testing plan once primary outcome is met
Login or create an account to see restricted content
REWIND: primary but not secondary outcomes were met
Login or create an account to see restricted content
REWIND: baseline characteristics
Login or create an account to see restricted content
REWIND: baseline CV disease and risk factors
Login or create an account to see restricted content
REWIND: baseline glucose-lowering medication and CV medication
Login or create an account to see restricted content
REWIND: medication used at last study visit
Login or create an account to see restricted content
REWIND
Login or create an account to see restricted content
REWIND: primary composite outcome of non-fatal MI, non-fatal stroke or death from CV or unknown causes
Login or create an account to see restricted content
REWIND: primary composite outcome of non-fatal MI, non-fatal stroke or death from CV or unknown causes
Login or create an account to see restricted content
REWIND: all-cause mortality
Login or create an account to see restricted content
REWIND: CV outcomes
Login or create an account to see restricted content
REWIND: primary composite outcome by baseline CV disease
Login or create an account to see restricted content
REWIND
Login or create an account to see restricted content
REWIND: composite microvascular outcome
Login or create an account to see restricted content
REWIND: composite kidney outcome of new macroalbuminuria, sustained decline in eGFR of ≥30 ml/min/1.73 m² or chronic RRT
Login or create an account to see restricted content
REWIND: kidney outcomes
Login or create an account to see restricted content
REWIND: eGFR and UACR over time
Login or create an account to see restricted content
REWIND: sensitivity analyses for a sustained decline in eGFR and UACR of ≥40 and ≥50 ml/min/1.73 m²
Login or create an account to see restricted content
REWIND
Login or create an account to see restricted content
REWIND: HbA1c and body weight over time
Login or create an account to see restricted content
REWIND: SBP and heart rate over time
Login or create an account to see restricted content
REWIND
Login or create an account to see restricted content
REWIND: safety summary
Login or create an account to see restricted content
REWIND
Login or create an account to see restricted content
REWIND: summary